- Motley Fool•7 days ago
Pfizer, Johnson & Johnson, and Roche are all poised to have a stellar 2017.
- Zacks•7 days ago
Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.
- Business Wire•8 days agoFDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application and granted Priority Review for TECENTRIQ® for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression ...
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.86|
|Dividend & Yield||1.02 (3.44%)|
|1y Target Est||N/A|